Cue Biopharma
Chemicals & Related Products · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
40 Guest St, Boston, Georgia, 31626, Uni...Phone Number
(617) 949-2680Website
www.cuebiopharma.comRevenue
$32.7 MillionStock Symbol
CUEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body to transform the treatment of cancer, infectious disease and autoimmune disease. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation. Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.Explore more
Cue Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cue Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Cue Biopharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cue Biopharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cue Biopharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Cue Biopharma
Product Launch: Get notified when Cue Biopharma launches new products
Earning: See what the market has to say on Cue Biopharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Cue Biopharma has new funding data
Cue Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Cue Biopharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Cue Biopharma
Compare insights from companies similar to Cue Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cue Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cue Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cue Biopharma.
Cue Biopharma financials insights
Gather financial insights about Cue Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Stock Offering
$66.2M
2022
Other Financing Round
$30M
2026
Stock/Share Issuance
$30M
Cue Biopharma Tech Stack
A closer look at the technologies used by Cue Biopharma
Most Recent Scoops
Person-Based
Events, Intellectual Property, Legal Affairs
Project
Cue Biopharma has announced that CUE-221, its novel anti-IgE therapy, is engineered with a dual mechanism of action that both neutralizes free IgE with high potency and down-regulates new IgE production, a combination designed to deliver deeper and more durable disease control across multiple allergic diseases.
Project
Cue Biopharma has announced CUE-401, a first-in-class bifunctional cytokine designed to target both IL-2 and TGF-β signaling within a single molecule to harness regulatory T cell function, which is advancing toward Phase I clinical development in autoimmune disease.
Partnership
Cue Biopharma has entered into a licensing agreement with Boehringer Ingelheim for CUE-501, a B-cell depleter, with the arrangement including potential for milestone payments.
Partnership
Partnership
Partnership
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cue Biopharma
Sign Up For FreeTo access detailed company insights
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body to transform the treatment of cancer, infectious disease and autoimmune disease. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alterat... Read More
